Detalhe da pesquisa
1.
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Lancet
; 403(10443): 2504-2519, 2024 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38795716
2.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Lancet
; 401(10378): 747-761, 2023 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746171
3.
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape.
Br J Dermatol
; 190(2): 149-162, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715694
4.
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial.
Br J Dermatol
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38576350
5.
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
J Am Acad Dermatol
; 90(3): 521-529, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871805
6.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Br J Dermatol
; 188(1): 22-31, 2023 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36689515
7.
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study.
J Eur Acad Dermatol Venereol
; 37(10): 2098-2108, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317022
8.
Yin and Yang of skin microbiota in "swimmer acne".
Exp Dermatol
; 31(6): 899-905, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35118730
9.
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.
Exp Dermatol
; 31(10): 1522-1532, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638561
10.
Early onset of senescence and imbalanced epidermal homeostasis across the decades in photoexposed human skin: Fingerprints of inflammaging.
Exp Dermatol
; 31(11): 1748-1760, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36320153
11.
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Br J Dermatol
; 187(6): 866-877, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35791755
12.
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
J Am Acad Dermatol
; 86(5): 1092-1101, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33493574
13.
An Open-Label, Prospective, Pilot Study of Hypertonic Saline for Hidradenitis Suppurativa.
Dermatol Surg
; 48(9): 954-960, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054049
14.
Effects of swimming on facial sebum in adolescents.
Pediatr Dermatol
; 39(3): 376-378, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34951051
15.
Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study.
J Med Internet Res
; 23(5): e23905, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33974549
16.
Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
Lancet
; 403(10427): 617-618, 2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38368012
17.
Revisiting the SUNSHINE and SUNRISE trials.
Lancet
; 403(10427): 616, 2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38368010
18.
What causes hidradenitis suppurativa ?-15 years after.
Exp Dermatol
; 29(12): 1154-1170, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33058306
19.
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council.
J Am Acad Dermatol
; 82(1): 117-122, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31425723
20.
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 82(4): 936-945, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31809827